TRU-015

DRUG3 trials

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer, Pfizer

Conditions

Arthritis, RheumatoidLymphoma, B-CellSystemic Lupus Erythematosus

Phase 1

Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus

TerminatedNCT00479622

Wyeth is now a wholly owned subsidiary of PfizerSystemic Lupus Erythematosus

Start: 2007-08-31End: 2008-05-31Target: 20Updated: 2008-05-08

Study Evaluating TRU-015 in B-Cell Non-Hodgkin's Lymphoma

TerminatedNCT00521638

Wyeth is now a wholly owned subsidiary of PfizerLymphoma, B-Cell

Start: 2007-09-30End: 2008-04-30Updated: 2021-02-18

Phase 2

Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis

TerminatedNCT00634933

PfizerArthritis, Rheumatoid

Start: 2008-03-31End: 2012-10-31Updated: 2013-03-11